Healthcare
Keros Therapeutics, Inc.(KROS)
Live Price
Offline$10.65
+2.31% today
1Y Change
-26.24%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $430.00M
- Revenue Growth
- +6775.0%
- EPS Growth
- +146.8%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Keros Therapeutics, Inc. (KROS) is a Healthcare stock with a market cap of $430.00M and listed on NASDAQ. The stock last traded around $10.65 and down 26.2% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +6775.0%, EPS growth of +146.8%, a dividend yield of 0.0%. What stands out right now is revenue +6775.0%, EPS +146.8%, free cash flow +165.1% with operating margin 28.9% and ROIC 20.9%. Valuation is more restrained than many high-expectation growth names at P/E 4.9 and price/sales 1.7. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines KROS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+6775.0% vs +7.6% peer median
Operating Margin
Above sector median
+28.9% vs +19.4% peer median
P/E
Below sector median
4.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 14, 2026 with an EPS surprise of -31.5% and a revenue surprise of -81.0%.
The operating story is still moving forward
Revenue is running at +6775.0% and EPS at +146.8%, with operating margin around 28.9%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 5, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | -31.5% | -4.5% | +2.1% | -7.6% |
2026 Mar 4, 2026 | -75.5% | -15.0% | -18.2% | -15.1% |
2025 Nov 5, 2025 | +83.8% | +3.3% | +11.6% | +29.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
KROS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
KROS Max Drawdown
-54.62%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KROS and SPY.
Company Overview
Keros Therapeutics, Inc.
NASDAQ Global Market
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
- Leadership
- Jasbir S. Seehra
- IPO Date
- Apr 8, 2020
- Employees
- 163
- Street Address
- 99 Hayden Avenue
- Mailing
- Lexington, MA, 02421
- Region
- Lexington, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 314 6297
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 4.9
- EV/EBITDA
- 1.9
- Price/Sales
- 1.7
- Price/Book
- 1.4
Growth
- Revenue
- +6775.0%
- EPS
- +146.8%
- Free Cash Flow
- +165.1%
Profitability
- Gross Margin
- 99.5%
- Operating Margin
- 28.9%
- Net Margin
- 35.7%
- ROE
- 14.3%
- ROIC
- 20.9%
Balance Sheet
- Debt/Equity
- 0.06
- Current Ratio
- 15.45
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.